Have a feature idea you'd love to see implemented?
Let us know!
AVXL Anavex Life Sciences Corp
Price (delayed)
$5.33
Market cap
$451.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.51
Enterprise value
$313.2M
Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease,
Highlights
The company's EPS rose by 23% YoY
Anavex Life Sciences's net income has increased by 20% YoY but it has decreased by 2.3% QoQ
AVXL's quick ratio is down by 19% QoQ and by 16% YoY
Anavex Life Sciences's equity has decreased by 12% YoY and by 3.8% QoQ
Key stats
What are the main financial stats of AVXL
Market
Valuations
Earnings
Shares outstanding
84.8M
Market cap
$451.96M
Enterprise value
$313.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$41.47M
EBITDA
-$41.47M
Free cash flow
-$30M
Per share
Balance sheet
Liquidity
EPS
-$0.51
Free cash flow per share
-$0.35
Book value per share
$1.53
Revenue per share
$0
TBVPS
$1.67
Total assets
$141.54M
Total liabilities
$11.75M
Debt
$0
Equity
$129.78M
Working capital
$129.78M
Debt to equity
0
Current ratio
12.04
Quick ratio
11.81
Net debt/EBITDA
3.35
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28.2%
Return on equity
-30.6%
Return on invested capital
N/A
Return on capital employed
-32%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVXL stock price
How has the Anavex Life Sciences stock price performed over time
Intraday
-1.11%
1 week
-3.18%
1 month
-4.14%
1 year
3.9%
YTD
-42.75%
QTD
-6.16%
Financial performance
How have Anavex Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.19M
Net income
-$41.53M
Gross margin
N/A
Net margin
N/A
Anavex Life Sciences's net income has increased by 20% YoY but it has decreased by 2.3% QoQ
AVXL's operating income is up by 12% year-on-year but it is down by 2.4% since the previous quarter
Growth
What is Anavex Life Sciences's growth rate over time
Valuation
What is Anavex Life Sciences stock price valuation
P/E
N/A
P/B
3.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 23% YoY
The stock's price to book (P/B) is 50% less than its 5-year quarterly average of 6.9 and 8% less than its last 4 quarters average of 3.8
Anavex Life Sciences's equity has decreased by 12% YoY and by 3.8% QoQ
Efficiency
How efficient is Anavex Life Sciences business performance
AVXL's return on assets is up by 16% year-on-year but it is down by 5% since the previous quarter
The ROE has grown by 16% YoY but it has contracted by 6% from the previous quarter
Dividends
What is AVXL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVXL.
Financial health
How did Anavex Life Sciences financials performed over time
Anavex Life Sciences's total liabilities has increased by 23% from the previous quarter and by 6% YoY
The company's current ratio fell by 20% QoQ and by 16% YoY
The debt is 100% smaller than the equity
Anavex Life Sciences's equity has decreased by 12% YoY and by 3.8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.